HIGHLIGHTS
- who: Noriko Fukuhara from the Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan have published the research work: Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study, in the Journal: (JOURNAL)
- what: The aims of the study were to identify the recommended dose of copanlisib in this patient group and assess the safety and antitumor activity of the copanlisib recommended dose. 72.0% of treated patients in the study showed a reduction in lesion size of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.